Project Description:
A PHASE II MULTICENTER, RANDOMIZED,
DOUBLE-BLIND, 12-WEEK TREATMENT, 3-ARM,
PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY
TO INVESTIGATE THE EFFICACY, SAFETY AND
TOLERABILITY OF RO7017773 IN PARTICIPANTS
AGED 15 TO 45 YEARS WITH AUTISM SPECTRUM
DISORDER (ASD)
To evaluate the efficacy of 12-week
treatment compared
with placebo in treating social
communication deficits in participants
with ASD age 15-45 years old